ArticleJournal of cardiovascular translational research2025
Exosomal miR-320c: A Novel Biomarker for Atrial Cardiomyopathy.
Article in Journal of cardiovascular translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extracellular Vesicles in Cardiovascular Disease: Intercellular Signaling, Liquid Biopsy Biomarkers, and Therapeutic Translation.Circulation research · 2026Review
- Genetics of supraventricular tachycardia: current evidence with a focus on translational relevance and personalized medicine.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Early diagnosis and treatment of atrial cardiomyopathy(ACM) are crucial for patients with atrial fibrillation(AF), and further exploration of its biomarkers remains necessary. High-throughput sequencing of exosomal miRNAs was performed on blood samples from patients with persistent AF (PeAF) exhibiting mild and severe left atrial fibrosis, with supraventricular tachycardia (SVT) patients. Quantitative real-time reverse transcription polymerase chain reaction analysis validated differentially expressed miRNAs (DE miRNAs) from severe left atrial fibrosis PeAF, SVT and health controls. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were conducted on target genes. Four exosomal DE miRNAs were identified, including miR-5106, let-7e-5p, miR-320c, and miR-382-3p. Exosomal miR-320c was down-regulated in severe left atrial fibrosis PeAF patients, while the other three miRNAs showed no significant changes. Exosomal miR-320c emerges as a potential biomarker for severe left atrial fibrosis and ACM, suggesting its suitability as a therapeutic target.
Indexed as
Identifiers
40465193What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.